Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tildrakizumab in Psoriatic Arthritis (INSPIRE LTE)
NCT04991116Phase 3Active, not recruiting
- Sponsor
- Sun Pharma
- Start
- Jun 2022
- Primary completion
- Dec 2028
- Modality
- Monoclonal Antibodies
- Countries
- 14
01
Overview
A Phase 3 trial of tildrakizumab in psoriatic arthritis (PsA), sponsored by Sun Pharma. Started Jun 2022; status: active, not recruiting.
02
Drugs
tildrakizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT04991116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04991116.